StockData
Halozyme Therapeutics, Inc. logo

Halozyme Therapeutics, Inc. (HALO) stock

HALONasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 13/3037% above fair value
$95.80−0.17 (-0.18%)

Close on Nov 18, 2026Market cap $10.87BP/E 28.3Yield –

Halozyme Therapeutics price to sales ratio

The price-to-sales ratio is market cap divided by revenue over the trailing twelve months.

Halozyme Therapeutics's price to sales ratio was 7.0× on Nov 11, 2026, against 6.8× a year earlier. Over the last 5 years it ranged from 5.2× to 14.3×, with a median of 7.3×.

Price to Sales Ratio at the end of each year

PeriodPeriod endValueChange (pts)
2026Nov 11, 20267.0×+0.6
2025Dec 31, 20256.4×−0.1
2024Dec 31, 20246.4×+0.2
2023Dec 29, 20236.3×−7.0
2022Dec 30, 202213.3×+1.0
2021Dec 31, 202112.2×−16.7
2020Dec 31, 202029.0×+16.2
2019Dec 31, 201912.8×+5.3
2018Dec 31, 20187.5×−9.8
2017Dec 29, 201717.4×+8.6
2016Dec 30, 20168.7×−7.3
2015Dec 31, 201516.0×−5.0
2014Dec 31, 201421.1×−5.6
2013Dec 31, 201326.7×−6.3
2012Dec 31, 201233.0×+15.7
2011Dec 30, 201117.2×–

More Halozyme Therapeutics figures

See a number that looks wrong?